Scarica l'app Stockscreener
20.37
1.75%
0.35
Pre-mercato:
20.18
-0.19
-0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
DNLI: Pivotal 2026 ahead with FDA review, new launches, and major clinical milestones in rare diseases - TradingView
Fisher Asset Management LLC Increases Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Wider Losses And New Shelf Registration - Sahm
Denali Therapeutics Inc. (DNLI) Investor Outlook: Analyzing The 56.80% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 182,183 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Jefferies reiterates Denali stock Buy rating on gene therapy outlook By Investing.com - Investing.com India
Jefferies reiterates Denali stock Buy rating on gene therapy outlook - Investing.com
BTIG Research Increases Denali Therapeutics (NASDAQ:DNLI) Price Target to $36.00 - MarketBeat
Denali Therapeutics Inc. Trade Ideas — GETTEX:4DN - TradingView
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - National Today
DNLI Should I Buy - Intellectia AI
Does Denali Therapeutics' (DNLI) Widening Quarterly Loss Reframe Its Pipeline-First Investment Narrative? - simplywall.st
Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Denali Therapeutics Q4 net loss deepens - TradingView
Denali Therapeutics (DNLI) widens 2025 loss but fortifies cash for key 2026 drug milestones - Stock Titan
Hunter syndrome drug nears April FDA call as Denali raises $475M - Stock Titan
Volume Recap: Is Denali Therapeutics Inc. a turnaround storyMarket Weekly Review & Weekly Chart Analysis and Guides - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Strong Buy Ratings Signal a 57% Potential Upside - DirectorsTalk Interviews
Wolfe Research initiates Denali Therapeutics stock with Peerperform - Investing.com
Wolfe Research initiates Denali Therapeutics stock with Peerperform By Investing.com - Investing.com UK
Wolfe Research Initiates Coverage of Denali Therapeutics (DNLI) with Peer Perform Recommendation - Nasdaq
(DNLI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Buyout Rumor: Is Denali Therapeutics Inc forming a bullish divergenceJuly 2025 Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Aug Action: Will ORKA stock recover after earningsInsider Selling & Weekly Setup with ROI Potential - baoquankhu1.vn
Aberdeen Group plc Buys 210,835 Shares of Denali Therapeutics Inc. $DNLI - Defense World
Denali Therapeutics (DNLI) Expected to Announce Earnings on Thursday - MarketBeat
Denali Therapeutics Inc. $DNLI Shares Sold by Thrivent Financial for Lutherans - Defense World
Pharma could be on the cusp of finally breaking the blood-brain barrier - Pharma Voice
Big Picture: Why is Denali Therapeutics Inc stock going downJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
How Denali Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - mfd.ru
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
(DNLI) Risk Channels and Responsive Allocation - Stock Traders Daily
Ideas Watch: Is Denali Therapeutics Inc. a turnaround storyEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Denali Therapeutics (DNLI) Valuation After WORLDSymposium Clinical Updates And Regulatory Progress - Sahm
Principal Financial Group Inc. Purchases 198,207 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Gets a Buy from Wedbush - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
Published on: 2026-02-08 06:47:50 - baoquankhu1.vn
Denali Therapeutics (NASDAQ:DNLI) Earns Buy Rating from BTIG Research - MarketBeat
Earnings Recap: Is Denali Therapeutics Inc forming a bullish divergenceBull Run & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - The Manila Times
Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop - MarketBeat
DNLI: Sustained biomarker normalization and clinical gains achieved in Hunter syndrome and MPS IIIA - TradingView
Denali Therapeutics Reports Promising Clinical Trial Data for Tividenofusp Alfa and Other Enzyme Replacement Therapies in Lysosomal Storage Disorders - Quiver Quantitative
Trial data track Denali enzyme drugs for rare brain and muscle diseases - Stock Titan
A Look At Denali Therapeutics (DNLI) Valuation As New ETV Rare Disease Data Presentations Approach - Yahoo Finance
How Denali’s Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors - Yahoo Finance
Denali Therapeutics Inc. (DNLI): Investor Outlook Reveals 44.49% Potential Upside In Neurodegenerative Drug Development - DirectorsTalk Interviews
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
Is Denali Therapeutics Inc stock suitable for long term investingJuly 2025 Sentiment & Weekly High Conviction Ideas - baoquankhu1.vn
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium - The Globe and Mail
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™ - The Manila Times
Denali to outline enzyme delivery to the brain in 2026 WORLDSymposium webcast - stocktitan.net
AlphaQuest LLC Raises Stake in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali Therapeutics Inc. stock benefit from infrastructure spendingTrade Ideas & Short-Term High Return Strategies - mfd.ru
(DNLI) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Denali Therapeutics (DNLI) Valuation As WORLDSymposium Data And FDA Priority Review Draw Closer - Sahm
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™ - The Manila Times
Denali to present clinical data on rare disease therapies at WORLDSymposium By Investing.com - Investing.com South Africa
Denali to present clinical data on rare disease therapies at WORLDSymposium - Investing.com Nigeria
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):